Robert Dillman | Chief Medical Officer
AIVITA Biomedical, Inc.

Robert O. (Bob) Dillman, M.D., is a Clinical Professor of Medicine at the University of California, Irvine, and since 2016 has been the Chief Medical Officer for AIVITA Biomedical Inc., Irvine, CA. Dr. Dillman received a B.A. from Stanford, M.D., internal medicine training, and Chief Resident certification from Baylor College of Medicine in Houston, then  hematology/oncology fellowship training at the University of California San Diego. He is board-certified in medical oncology, hematology, and internal medicine. For 25 years, he directed the Hoag Cancer Center in Newport Beach, CA, where he was consistently named one of the Best Doctors in America, directed a cell biology laboratory that conducted cutting-edge bench-to-bedside translational research in patient-specific cellular immunotherapies, served as education director and research director for the cancer program, conducted clinical research trials, chaired multidisciplinary specialized tumor boards, and analyzed Cancer Registry data for the largest cancer program in Southern California outside of Los Angeles. He was a founding member, a 2-time Board Member, and the 9th president of the Society for the Immunotherapy of Cancer (SITC). He chaired the Cancer Biotherapy Research Group (CBRG) for more than a decade. His research career has focused on cancer biotherapy and immunotherapy, including pioneering work with monoclonal antibodies and immunoconjugates, and patient-specific cellular immunotherapies such as LAK, TIL, and autologous tumor cell line and dendritic cell vaccines. He personally wrote 252 of his 328 medical and scientific publications and has delivered more than 1000 oral presentations, including a plenary presentation at the American Society for Clinical Oncology (ASCO).